Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: Evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 916-922

  Lepist, Eve Irene ^a   Damaraju, Vijaya L ^b   Zhang, Jing ^b   Gati, Wendy P ^b   Sylvia Y M Yao, ^b   Smith, Kyla M ^b   Karpinski, Edward ^b   Young, James D ^b   Leung, Kwan H ^c   Cass, Carol E ^b  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; FLUDARABINE; MEMBRANE PROTEIN; NITROBENZYLTHIOINOSINE; PRODRUG; RECOMBINANT CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; RECOMBINANT CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; RECOMBINANT CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; RECOMBINANT EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RECOMBINANT EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; RECOMBINANT PROTEIN; TECADENOSON; UNCLASSIFIED DRUG; 4-NITROBENZYLTHIOINOSINE; ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; DRUG DERIVATIVE; FURAN DERIVATIVE; MERCAPTOPURINE RIBOSIDE; NUCLEOSIDE TRANSPORTER; SLC29A1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; AFFINITY LABELING; ANIMAL; BRAIN; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

MURINAE; MUS;

ADENOSINE; ADENOSINE A1 RECEPTOR AGONISTS; AFFINITY LABELS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FURANS; HUMANS; MEMBRANE TRANSPORT MODULATORS; MICE; NUCLEOSIDE TRANSPORT PROTEINS; PRODRUGS; THIOINOSINE;

EID: 84875867483     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049858     Document Type: Article

References (33)

1. Adjei AA, Dagnino L, Wong MM, and Paterson AR (1992) Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol 31:71-75.
2. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L, Tellez J, Ritzel MW, and Claycomb WC, et al. (2006) Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99:510-519.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, and Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536.
5. Dhalla AK, Shryock JC, Shreeniwas R, and Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369-385.
6. King AE, Ackley MA, Cass CE, Young JD, and Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416-425.
7. Lerman BB, Ellenbogen KA, Kadish A, Platia E, Stein KM, Markowitz SM, Mittal S, Slotwiner DJ, Scheiner M, and Iwai S, et al. (2001) Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther 6:237-245.
8. Lu H, Chen C, and Klaassen C (2004) Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos 32:1455-1461.
9. Lynch TP, Paran JH, and Paterson AR (1981) Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 59-monophosphate. Cancer Res 41:560-565.
10. Ogbunude PO, Gati WP, and Paterson AR (1984) Dephosphorylation of nitrobenzylthioinosine 59-monophosphate by ecto 59-nucleotidase of HeLa cells. Biochem Pharmacol 33:3561-3566.
11. Parkinson FE, Damaraju VL, Graham K, Yao SY, Baldwin SA, Cass CE, and Young JD (2011) Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem 11:948-972.
12. Peterman C and Sanoski CA (2005) Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev 13:315-321.
13. Rahn JJ, Kieller DM, Tyrrell DL, and Gati WP (1997) Modulation of the metabolism of beta-L- (-)-29,39-dideoxy-39-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother 41:918-923.
14. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, and Young JD (1997) Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272:C707-C714.
15. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, and Young JD (1998) Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 15: 203-211.
16. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, and Chen XZ, et al. (2001) Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276: 2914-2927.
17. Schaddelee MP, Voorwinden HL, Groenendaal D, Hersey A, Ijzerman AP, Danhof M, and De Boer AG (2003) Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships. Eur J Pharm Sci 20:347-356.
18. Schaddelee MP, Read KD, Cleypool CG, Ijzerman AP, Danhof M, and de Boer AG (2005) Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. Eur J Pharm Sci 24:59-66.
19. Smith KM, Ng AM, Yao SY, Labedz KA, Knaus EE, Wiebe LI, Cass CE, Baldwin SA, Chen XZ, and Karpinski E, et al. (2004) Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol 558: 807-823.
20. Smith KM, Slugoski MD, Cass CE, Baldwin SA, Karpinski E, and Young JD (2007) Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3. Mol Membr Biol 24:53-64.
21. Vickers MF, Mani RS, Sundaram M, Hogue DL, Young JD, Baldwin SA, and Cass CE (1999) Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochem J 339: 21-32.
22. Vickers MF, Kumar R, Visser F, Zhang J, Charania J, Raborn RT, Baldwin SA, Young JD, and Cass CE (2002) Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. Biochem Cell Biol 80:639-644.
23. Wiebe LI, Knaus EE, Gati WP, Iwashina T, and McQueen L (1990) Drug-induced perturbations in the in vivo distribution of oncological radiotracers-II. 5-[125I]iodo-29-deoxyuridine influenced by nitrobenzylthioinosine-59-phosphate (NBMPR-P) and acyclothymidine (ACT). Int J Rad Appl Instrum [A] 41:159-162.
24. Wright AM, Gati WP, and Paterson AR (2000) Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 14:52-60.
25. Yao SY, Ng AM, Vickers MF, Sundaram M, Cass CE, Baldwin SA, and Young JD (2002) Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J Biol Chem 277:24938-24948.
26. Yao SY, Ng AM, Cass CE, Baldwin SA, and Young JD (2011) Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem 286:32552-32562.
27. Yao SYM, Cass CE, and Young JD (2000) The Xenopus oocyte system for the expression cloning and characterization of plasma membrane transport proteins, Oxford University Press, Oxford.
28. Young JD, Yao SY, Sun L, Cass CE, and Baldwin SA (2008) Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38: 995-1021.
29. Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LP, Nowak I, Karpinski E, Baldwin SA, and Young JD, et al. (2005) Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol Pharmacol 68:830-839.
30. Zhang J, Smith KM, Tackaberry T, Sun X, Carpenter P, Slugoski MD, Robins MJ, Nielsen LP, Nowak I, and Baldwin SA, et al. (2006a) Characterization of the transport mechanism and permeant binding profile of the uridine permease Fui1p of Saccharomyces cerevisiae. J Biol Chem 281:28210-28221.
31. Zhang J, Sun X, Smith KM, Visser F, Carpenter P, Barron G, Peng Y, Robins MJ, Baldwin SA, and Young JD, et al. (2006b) Studies of nucleoside transporters using novel autofluorescent nucleoside probes. Biochemistry 45:1087-1098.
32. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 64:1512-1520.
33. Zhang J, Visser F, King KM, Baldwin SA, Young JD, and Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26:85-110.